PMVPHealthcare · BiotechnologyPMVP Stock Forecast: PMV Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering PMV Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +236.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 8 Aug 2026 — in the upper half.
PMVP stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores PMV Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (80): Smaller than most of the companies we track.
Value (18): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own PMV Pharmaceuticals, Inc. — and when they’d sell — is the membership.
PMVP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PMVP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +236.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 July 2026 | Ladenburg Thalmann | Assumes | Buy | $3.00 |
| 13 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | Craig-Hallum | Initiates | Buy | — |
| 12 Apr 2024 | Jefferies | Initiates | Buy | — |
| 7 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Dec 2023 | Ladenburg Thalmann | Initiates | Buy | — |
| 16 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2023 | Oppenheimer | Reiterates | Outperform | — |
| 20 Mar 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Mar 2023 | Oppenheimer | Maintains | Outperform | — |
| 17 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 June 2022 | Oppenheimer | Maintains | Outperform | — |
| 24 May 2022 | Goldman Sachs | Maintains | Buy | — |
| 2 Mar 2022 | Oppenheimer | Upgrade | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PMVP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
PMV Pharmaceuticals, Inc. (PMVP) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.8×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- 0.4×
Cheaper than 81% of US stocks
Cheaper than 80% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 33% of US stocks
Higher than 30% of US stocks
- Return on equity
- −63.2%
- Return on assets
- −39.1%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PMVP vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PMVP appears on the weeks it earns a place.
Frequently asked questions about PMVP stock
What is the PMVP stock price forecast for 2026-2027?
The 5 Wall Street analysts covering PMV Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PMVP stock a buy right now?
Of the 5 analysts covering PMV Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PMV Pharmaceuticals, Inc. 63 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PMVP?
As at 8 Aug 2026, PMV Pharmaceuticals, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).
Will PMVP stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +236.1% from the last close, and Ticker Nerd's factor model ranks PMV Pharmaceuticals, Inc. 63 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PMVP stock forecast for 2030?
No analyst covering PMV Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMVP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.
How has PMVP stock performed over the past year?
PMV Pharmaceuticals, Inc. returned -17.9% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does PMV Pharmaceuticals, Inc. do?
Pmv Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations.
About PMV Pharmaceuticals, Inc.
Pmv Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations. As a public entity in the biotech sector, Pmv Pharmaceuticals contributes to advancing cancer treatment by addressing these commonly mutated genes. The company's primary objective is to create therapeutic compounds that can reactivate normal p53 protein functions, thereby inhibiting tumor growth in various forms of cancer. Founded with expertise in structural biology and drug design, Pmv Pharmaceuticals operates at the intersection of innovation and precision medicine, aiming to introduce new cancer treatments with potentially significant clinical impact. The company's ongoing research and development efforts are primarily aimed at improving patient outcomes for those suffering from malignancies associated with p53 mutations, a critical unmet medical need in oncology. In the financial markets, Pmv Pharmaceuticals Inc. is a significant player within the biotechnology industry, attracting attention from investors focused on innovative cancer therapies and the broader field of genomic medicine.
CEO Dr. David H. Mack Ph.D. · 54 employees · United States · https://www.pmvpharma.com